-Hindustan Times The government is set to re-launch its pharmacy chain, Jan Aushadhi, to sell generic drugs ranging from anti-biotics, anti-cardiac, anti-infective and gastro intestinal drugs at prices at least half of branded drugs. The project would be launched in six states on a pilot basis from June 21, where 5,000 stores would be opened across the country in a phased manner. The scheme failed in 2008 due to poor supply-chain management. “Now, we...

-Economic and Political Weekly Ten years on, the progressive provisions of the amended Indian Patents Act are being watered down. Ten years have passed since the Indian Patents Act, 1970 was amended in 2005 to bring the country’s laws in line with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The most important of the 2005 amendments was the introduction of product patents for 20 years, including for pharmaceutical products,...

-The Hindu Business Line Generic prescription patterns, supply-chain management must for low-cost drug availability An earnest-sounding voice answers the Jan Aushadhi hotline number and assures the person calling that more stores are being planned by the Government in districts across the country. That response was to the caller’s query if there was a Jan Aushadhi (JA) store in Mumbai. As it happens, there is one in Maharashtra, but in Pune! It’s been over...

-The Hindu It was resolved that all IMA members shall write drugs with chemical or generic name in capital letters A resolution was passed at the recent working committee meeting of the Indian Medical Association (IMA) that is likely to have the direct benefit of making drugs more accessible and affordable. It was resolved that all IMA members “shall write drugs with chemical or generic name in capital letters, and the name of...

-The Hindu Business Line Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on...